Jefferies Upgrades Editas Medicine (EDIT) to Buy

August 10, 2016 6:41 AM EDT
Get Alerts EDIT Hot Sheet
Price: $15.99 -4.25%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 36 | New: 11
Trade EDIT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies upgraded Editas Medicine (NASDAQ: EDIT) from Hold to Buy with a price target of $35.00, saying LCA10 IND remains on track.

Analyst Gena Wang commented, "EDIT announced collaboration with ADVM today on AAV vectors in eye indications, which along with other partnerships further enhances the tech capability. EDIT remains on track to file LCA10 IND in 2017 to potentially establish clinical POC. While our PT remains unchanged, recent pullback due to lockup expiry and general weakness in the SMID cap biotech sector provides an oppt to participate in the transformative CRIPSR technology. Upgrade to Buy."

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $23.28 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Upgrades

Related Entities

Jefferies & Co, Gena Wang

Add Your Comment